AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots Phase 3

This morning, AtaiBeckley shared positive topline data from the open-label portion of its Phase 2b trial of intranasal 5-MeO-DMT (BPL-003) in patients with treatment-resistant depression (TRD).

The open-label extension (OLE) saw participants offered a second, 12 mg dose of the short-acting psychedelic after the 8-week blinded period during which they received one of three first doses (0.3 mg, 8 mg, or 12 mg).

AtaiBeckley, which just last week adopted its present name after a merger between atai Life Sciences and Beckley Psytech closed, reports that the second dose “produced additional rapid, clinically meaningful antidepressant effects that were sustained for up to eight weeks”.

We reviewed the readout and spoke with AtaiBeckley CEO, Srinivas Rao, to dive a little deeper…